Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Closed 06-02 16:00:00 EDT

452.86

-28.37

-5.90%

盘后449.00

-3.86-0.85%

19:46 EDT

High476.96	Low451.74	Vol427.20K
Open475.80	D1 Closing481.23	Amplitude5.24%
Mkt Cap10.44B	Tradable Cap4.98B	Total Shares23.06M
T/O196.40M	T/O Rate3.88%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":452.86,"timestamp":1780430400000,"preClose":481.23,"halted":0,"volume":427196,"hourTrading":{"tag":"盘后","latestPrice":449,"preClose":452.86,"latestTime":"19:46 EDT","volume":1998,"amount":903444.42,"timestamp":1780443964665,"change":-3.86,"changeRate":-0.008524,"amplitude":0.008524},"delay":0,"changeRate":-0.058953099349583364,"floatShares":11000087,"shares":23055522,"eps":-13.648958,"marketStatus":"Closed","change":-28.37,"latestTime":"06-02 16:00:00 EDT","open":475.8,"high":476.96,"low":451.74,"amount":196398448.246,"amplitude":0.052407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.648958,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780473600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":481.23,"preHourTrading":{"tag":"盘前","latestPrice":476.99,"preClose":481.23,"latestTime":"09:28 EDT","volume":207,"amount":99100.28952,"timestamp":1780406885583,"change":-4.24,"changeRate":-0.008811,"amplitude":0.01519},"postHourTrading":{"tag":"盘后","latestPrice":449,"preClose":452.86,"latestTime":"19:46 EDT","volume":1998,"amount":903444.42,"timestamp":1780443964665,"change":-3.86,"changeRate":-0.008524,"amplitude":0.008524},"volumeRatio":1.545489,"impliedVol":0.418,"impliedVolPercentile":0.0797},"requestUrl":"/m/hq/s/MDGL/tweets","defaultTab":"tweets","newsList":[{"id":"2640540998","title":"Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2640540998","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640540998?lang=en_us&edition=fundamental","pubTime":"2026-06-02 07:49","pubTimestamp":1780357783,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Chief Medical Officer David Soergel sold 1,042 common shares on June 1, 2026 at USD 495.74.The sale was executed under a Rule 10b5-1 trading plan adopted on March 2, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLb02Nqd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639869030","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2639869030","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639869030?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:14","pubTimestamp":1779984896,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) drew fresh attention after releasing new Phase 3 and real world data on its MASH drug Rezdiffra, ahead of detailed presentations at the EASL Congress 2026 in Barcelona.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe latest Rezdiffra data appear to be feeding into sentiment, with Madrigal’s 90 day share price return of 18.35% contrasting with a year to date share price decline of 11.15%, while the 1 year total shareholder return of 94.81% points to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638664012","title":"Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2638664012","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638664012?lang=en_us&edition=fundamental","pubTime":"2026-05-28 18:15","pubTimestamp":1779963324,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $620.00. Andrew Fein has gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-madrigal-pharmaceuticals-maintains-620-price-target-on-strengthened-rezdiffra-mash-and-cardiometabolic-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-madrigal-pharmaceuticals-maintains-620-price-target-on-strengthened-rezdiffra-mash-and-cardiometabolic-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638958507","title":"Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients With Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2638958507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638958507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUABZS6XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638551159","title":"Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638551159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638551159?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:40","pubTimestamp":1779795643,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals (MDGL) and Edgewise Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-madrigal-pharmaceuticals-mdgl-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-madrigal-pharmaceuticals-mdgl-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL","BK4585","BK4007","BK4139","BK4539","BK4588","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347817","title":"Madrigal director Richard S. Levy disposes of USD 2.4 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347817","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347817?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:02","pubTimestamp":1779487352,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals director Richard S. Levy sold 5,642 shares of common stock on May 22, 2026.Sales were executed at weighted average prices ranging from $506.68 to $519.98 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLb2WQSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Madrigal director Richard S. Levy disposes of USD 2.4 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","MDGL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637512873","title":"Madrigal Pharmaceuticals grants 5,308 inducement RSUs to 15 new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2637512873","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637512873?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:06","pubTimestamp":1779393986,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 5,308 time-based restricted stock units to 15 new non-executive employees on May 15, 2026 under its 2025 Inducement Plan.The awards vest in four equal annual installments on the first through fourth anniversaries of the grant date.Vesting is contingent on continued employment through each vesting date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL12P1dv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","SG9999014005.SGD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","IE00BGHQF748.EUR","MDGL","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4588","IE00BN0W2W23.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637354646","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637354646","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637354646?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:05","pubTimestamp":1779393900,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., May  21, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299716/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635736684","title":"Madrigal Pharmaceuticals Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2635736684","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635736684?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:15","pubTimestamp":1778685300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 11:15 ET (15:15 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878037","title":"Truist Raises Price Target on Madrigal Pharmaceuticals to $709 From $640, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878037","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635878037?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:17","pubTimestamp":1778678250,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) has an average rating of buy and mean price target of $679.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635877657","title":"BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2635877657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635877657?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:08","pubTimestamp":1778677729,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio HoldingsWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL6N41Q0SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935042991.SGD","LU1718418525.SGD","LU0348827113.USD","LU0683600562.USD","LU2602419157.SGD","LU0326950275.SGD","LU0819121731.USD","LU0963586101.USD","LU2087589342.USD","LU2468319806.SGD","LU1496350502.SGD","IE00B0JY6N72.USD","LU0061477393.USD","BABA","LU1688375341.USD","LU0823397285.USD","SG9999011175.SGD","HK0000320264.USD","LU0124676726.USD","LU0259732245.USD","SG9999000327.SGD","LU1051768304.USD","IE00BZ08YT58.USD","LU0051755006.USD","LU1121112475.USD","LU1366334578.USD","LU0795875169.SGD","IE00B42XCP33.USD","LU0820561909.HKD","LU2089984988.USD","LU0048580855.USD","LU0642271901.SGD","LU0210536198.USD","BK4007","IE00BF5LJ272.USD","LU0072462343.USD","LU1244550221.USD","LU0225771236.USD","LU0320765992.SGD","BK4170","LU0384037296.USD","LU0359201612.USD","LU0011963245.USD","LU2129689605.HKD","LU1066051225.USD","LU2039709279.SGD","LU1069347547.HKD","LU0348783233.USD","BK4603","SG9999001226.SGD","LU0873338254.USD","LU0553294199.USD","LU0890818403.SGD","LU1303224171.USD","LU2294711713.HKD","FLNC","IE00BPRC5H50.USD","LU0130103400.USD","LU2487616109.SGD","LU0577902371.SGD","MDGL","LU0348735423.USD","SGXZ86797644.SGD","LU1251922891.USD","LU0061475181.USD","BK4503","LU0348816934.USD","LU0593848301.USD","LU0359202008.SGD","IE00B29SXK94.USD","LU0287142896.SGD","BIRK","LU0348805143.USD","LU0886674414.USD","LU0106959298.USD","SG9999001051.SGD","LU0545039389.USD","LU1551013425.SGD","LU0345769128.USD","IE00B5MMRT66.SGD","LU0052750758.USD","LU0889565916.HKD","BK4081","LU0306806265.USD","BK4559","LU1057294990.SGD","LU0143863198.USD","LU0531970944.HKD","STX","LU1152091754.HKD","SG9999002224.SGD","SG9999014674.SGD","LU0456842615.SGD","LU0823040885.USD","LU0898667661.SGD","SG9999003800.SGD","BK4599","LU2430703178.SGD","HK0000320223.HKD","LU0787776722.HKD","LU0463099449.HKD","LU1769817179.HKD","LU2293587155.HKD","LU1548497426.USD","LU0543330566.HKD","LU0689472784.USD","SGXZ57979304.SGD","LU0823426308.USD","IE00B4R5TH58.HKD","LU2505996681.GBP","LU1267930227.SGD","LU0762542818.HKD","LU0315178854.USD","LU2357305700.SGD","LU1093756168.USD","LU0164872284.USD","LU0918141887.USD","LU1807302812.USD","LU1032466523.USD","SG9999001903.USD","HK0000107257.USD","LU1196500208.SGD","LU1894683348.USD","HBBD.SI","IE00B2B36J28.USD","LU0823413587.USD","BABX","IE00BKVL7J92.USD","IE00BZ08YR35.GBP","LU1282651048.USD","WIX","IE00B3PB1722.GBP","LU1008478684.HKD","LU0417516902.SGD","LU1880398554.USD","LU0130518102.USD","NEBX","BK4579","LU2756315664.SGD","LU1732799900.SGD","LU0943347566.SGD","NBIZ","LU2471134879.HKD","BK1608","IE00BN8TJ469.HKD","LU0823397103.USD","LU0577902611.USD","LU2045819591.USD","SG9999002562.SGD","LU0630378429.USD","LU1235294995.USD","LU1261432733.SGD","LU0708995583.HKD","LU0588546209.SGD","LU0823431647.USD","GB00BDT5M118.USD","LU1670628061.USD","LU1048596156.SGD","BK4121","LU0348788117.USD","LU2430703251.USD","LU0828237510.HKD","LU2097828714.EUR","LU0210526637.USD","BK1517","IE00B7SZL793.SGD","LU2750360641.GBP","LU0321505439.SGD","REPL","LU0081259029.USD","IE00BVYPNW00.USD","LU1823568750.SGD","LU0964807845.USD","CDRE","LU0985481810.HKD","IE00BFXG1179.USD","LU0501845795.SGD","SGXZ90724238.SGD","09988","LU1960683339.HKD","BK4502","LU1046421795.USD","SG9999001689.USD","BK1618","LU0689626769.HKD","LU2148611432.USD","LU1242518857.USD","LU0516423174.USD","LU0516422952.EUR","LU0791590937.USD","LU2399975544.HKD","LU0889566641.SGD","LU1282651121.HKD","LU0791591158.USD","LU0588545730.USD","LU1732800096.USD","LU0197773673.USD","LU1043141123.HKD","BK4550","BK4558","LU0868494617.USD","LU1515016050.SGD","LU1883839398.USD","EOSU","LU1162221912.USD","IE0034224299.USD","BK4116","LU2294711473.HKD","SG9999001093.SGD","LU0630378692.HKD","NBIG","LU2112291526.USD","BK4533","SG9999001176.USD","EOSE","LU1169590202.USD","LU0169518387.USD","BK4560","LU0823413660.USD","AEP","LU0056508442.USD","LU2097828631.EUR","LU2097828805.USD","LU1228905037.USD","QURE","HK0000306701.USD","LU1880398471.USD","LU2357125470.USD","LU1815336760.USD","IE00BVYPNV92.GBP","BK4122","LU1152091168.USD","LU2133065610.SGD","BK4592","LU0594300419.USD","LU0122379950.USD","LU1778281490.HKD","LU1808992512.USD","LU2505996509.AUD","LU1880383366.USD","LU0132412106.USD","LU0143863784.USD","BK4213","LU2226246903.HKD","LU2249611893.SGD","LU0868486357.SGD","LU0499858438.USD","LU0828237940.HKD","LU1551013342.USD","BK1591","LU0823414551.USD","LU0048597586.USD","BK4532","LU1568876335.HKD","ORLA","LU2129689431.USD","LU1878469433.USD","LU0795875086.SGD","LU2097829019.USD","LU0516422440.USD","LU1032955483.USD","LU1023057109.AUD","BK4157","IE0002141913.USD","LU2471134796.USD","IE00B66KJ199.SGD","BK1501","LU0084288322.USD","LU0310800965.SGD","LU0572939691.SGD","BK1615","LU0170899867.USD","LU1439103000.SGD","LU0128522157.USD","LU0540923850.HKD","IE000M9KFDE8.USD","IE00BMPRXN33.USD","LU0345770308.USD","LU0607220059.USD","LU2023250330.USD","LU1201861165.SGD","LU0417516738.SGD","LU0737861699.HKD","BK4146","LU0577902454.USD","LU1852331112.SGD","LU2506951792.HKD","LU0880133367.SGD","LU0096374516.USD","SG9999006514.SGD","LU2236285917.USD","IE00B3M56506.USD","LU0229945570.USD","IE000SO60NU8.SGD","LU0661504455.SGD","LU2242644610.SGD","WDCX","BK1142","LU0164880469.USD","IE00BJT1NW94.SGD","LU0054237671.USD","LU0211977185.USD","LU1769817096.USD","IE0000B7K699.USD","LU0543330483.HKD","LU0128525689.USD","LU0234572021.USD","LU0455707207.USD","LU0149721374.USD","LU0531971165.HKD","LU1861220033.SGD","LU0196878994.USD","LU0348784397.USD","BK4105","LU0306807586.USD","LU0950373646.USD","LU0251143458.SGD","LU1282649810.SGD","LU2125910500.SGD","LU1093756325.SGD","LU0225284248.USD","BK4187","LU1642822792.SGD","BK4588","LU0058720904.USD","LU0516423091.SGD","BK4527","LU0234570918.USD","LU0949170772.SGD","LU2471134523.USD","BK1502","LU0320764243.SGD","LU1244550577.SGD","HK0000286598.CNH","LU1066051498.USD","LU0648000940.SGD","LU1188198961.HKD","IE00BJJMRZ35.SGD","LU1674673691.USD","WOLF","LU0502904849.HKD","LU1242518931.SGD","LU0114720955.EUR","LU0348825331.USD","LU0264606111.USD","LU0823426480.USD","LU0469268626.HKD","LU0957808578.USD","LU0329931090.USD","SG9999001440.SGD","SG9999004220.SGD","LU1328615791.USD","IE000F7OJYX1.SGD","LU3063872942.SGD","LU1719994722.HKD","LU1868838027.USD","IE00BLSP4239.USD","LU0054450605.USD","LU0327786744.USD","RCAT","LU1770036033.HKD","LU0605514214.HKD","LU1023059063.AUD","LU0865486749.SGD","LU1228905540.USD","LU1051769294.HKD","WDC","LU0321505868.SGD","BK4581","BK4535","LU0348783662.USD","LU0203347892.USD","LU1568876251.USD","LU1961090484.USD","LU0651946864.USD","LU0048388663.USD","LU0231483743.USD","IE0002270589.USD","LU1794554557.SGD","LU1813983027.USD","LU1211504680.USD","LU0432979614.USD","LU0784639295.USD","LU0314106906.USD","LU1720051017.SGD","LU1981816686.USD","LU0417516571.SGD","IE00BZ1G4Q59.USD","BK4512","LU0918141705.HKD","LU1044876610.USD","SG9999002828.SGD","DT","HK0000151867.HKD","LU1861215975.USD","LU1059921491.USD","IE000BZT7R73.USD","LU0640798160.USD","LU0488056044.USD","LU1316542783.SGD","SG9999002232.USD","LU0251144936.SGD","LU0293314216.USD","LU0994945656.USD","LU1810669033.SGD","NBIS","LU1044875133.USD","LU0608807946.USD","IE00BGHQF631.EUR","SG9999000459.SGD","SNXX","LU1221951046.USD","BK4139","LU2750360997.AUD","HK0000306685.HKD","BK4077","LU1061106388.HKD","LU0856984785.SGD","IE00B7SZLL34.SGD","IE000MB6IJN5.SGD","LU0456827905.SGD","BK4554","LU0396098781.USD","BK4519","LU1048484197.HKD","LU1328277881.USD","SGXZ62798434.SGD","LU2476274720.SGD","LU0640476718.USD","IE00B543WZ88.USD","REI","LU1670627923.USD","BABW","LU0738911758.USD","IE00BLSP4452.SGD","LU1504937902.USD","LU2125910849.SGD","LU0070217475.USD","BBYY","BK4505","LU0594300179.USD","IE00BFMHRM44.USD","LU1115378108.SGD","LU0651947912.USD","LU0823039010.USD","LU2456880835.USD","LU0477156797.USD","LU0289739699.SGD","LU0320764599.SGD","ASRT","LU0072913022.USD","BK4548","LU0106261612.USD","LU0426417589.USD","LU1929549753.HKD","LU2756315318.SGD","LU0449509016.USD","IE00B3T34201.USD","IE0009355771.USD","LU1914381329.SGD","LU1048588211.SGD","LU1366334651.USD","VELO","LU1066051811.HKD","LU0164865239.USD","IE00B1BXHZ80.USD","LU0611395673.USD","BK4575","LU2476274308.USD","LU1720050803.USD","BK4504","LU0049853897.USD","LU0345776255.USD","LU1224709979.USD","LU0476273544.USD","LU1642822529.SGD","ALBmain","PSNL","LU0235996351.USD","LU0370786039.SGD","LU0244354667.USD","BK4565","LU0029875118.USD","LU0254981946.USD","LU2430703095.HKD","IE00BZ08YS42.EUR","SG9999002463.SGD","BK4609","LU2592432038.USD","LU0307460666.USD","LU0648948544.HKD","SG9999001176.SGD","LU0320765646.SGD","IE00BBT3K403.USD","LU0106252389.USD","LU0650527681.SGD","LU0117841782.USD","LU0449515922.USD","LU0531971595.HKD","LU1044874839.SGD","LU0098860793.USD","LU2778985437.USD","LU0054578231.USD","LU0823038988.USD","LU0345775950.USD","BABO","LU1956131251.USD","LU1066053197.SGD","LU0128522744.USD","IE00B19Z4B17.USD","LU1196710864.SGD","LU0577902298.EUR","BK4534","LU0456846285.SGD","LU2129689514.USD","LU0320764755.SGD","LU0173614495.USD","BABU","LU0043850808.USD","LU0181495838.USD","IE00BDGV0183.EUR","LU0039217434.USD","LU0127658192.USD","LU0499858602.USD","LU0261950983.USD","IE0032431581.USD","LU0541501648.USD","LU0441854154.USD","SG9999013999.USD","LU2097828557.USD","LU0261947096.USD","BK4526","LU0444973449.USD","LU1720051108.HKD","LU0823041008.USD","LU0672654166.SGD","LU0210527791.USD","LU2403377893.USD","LU1046422090.SGD","LU0012050646.USD","LU0589944569.HKD","IE0034235303.USD","LU1169589451.USD","IE00BMPRXR70.SGD","LU0329678337.USD","LU0675040207.SGD","IE00B19Z3581.USD","LU1035773651.USD","IE00B19Z9P08.USD","LU0214875030.USD","LU1282649141.HKD","LU0762541174.USD","LU2213496289.HKD","IE0003895053.USD","LU0315179316.USD","LU0634319403.HKD","LU0165289439.USD","LU1282649067.USD","LU2152927971.USD","IE00BSNM7G36.USD","LU1105468828.SGD","BK1610","IE00B0169N27.USD","LU0329678170.USD","LU0823431563.USD","BK1586","LU1831875114.USD","LU1983299246.USD","LU0053666078.USD","LU1145028129.USD","LU0149534421.HKD","LU0329931173.USD","LU0109394709.USD","LU0757428866.USD","LU0831093199.SGD","SG9999006597.SGD","LU0314109678.HKD","LU0823414478.USD","89988","LU0047713382.USD","LU0345769631.USD","LU0426412945.USD","LU1993786604.SGD","LU1224444064.USD","BK4531","LU0985320562.USD","BK4607","LU0572940350.SGD","LU1815336091.USD","LU0588545904.SGD","BK1249","IE00B19Z9Z06.USD","LU0228367735.SGD","BK4543","LU0862451753.SGD","IE0031619046.USD","JNJ","LU0792757196.USD","LU0203345920.USD","LU0466842654.USD","BK4161","LU0359201885.HKD","BK4220","LU1244550494.USD","LU1770034418.SGD","LU0708995153.HKD","BK4538","LU0588545490.SGD","LU1894683264.USD","LU0456855351.SGD","IE0008368304.USD","RCAX","LU0348723411.USD","LU0228659784.USD","IE0001KFT4U8.USD","LU0541502299.USD","LU0979878070.USD","LU0819123356.HKD","LU2896262040.SGD","BK1588","IE000WAW04H5.SGD","LU1280957306.USD","LU0572944931.SGD","LU1074936037.SGD","KBAB","IE00BFTCPJ56.SGD","LU0700851271.USD","LU0210528500.USD","LU0140636845.USD","BK1575","BK4023","LU2097828474.EUR","LU1655091459.SGD","BK4606","NBIL","LU0545562505.USD","LU0821914370.USD","BK4614","LU0067412154.USD","IE00B894F039.SGD","LU0762540952.USD","BK4196","LU2488822045.USD","BK4097","LU1323998911.USD","LU1629891620.HKD","LU0820562030.AUD","LU2417539215.USD","LU0106259558.USD","LU0516422366.SGD","LU0197773160.USD","AEIS","LU0431992006.USD","LU0820561818.USD","LU0862451837.USD","BK4524","LU0608807433.USD","BK1521","LU2257852520.SGD","LU0561508036.HKD","LU0871576103.HKD","LU1506573853.SGD","LU1430594728.SGD","LU1868837565.USD","LU1674673428.USD","LU0577902538.SGD","BK4141","BK4587","LU0029874905.USD","LU0345770993.USD","LU0797268264.HKD","LU2449936058.SGD","BK4096","LU0348814723.USD","LU0163747925.USD","SNDK","LU1003077747.HKD","LU0052756011.USD","LU1880383440.USD","IE00B29SXL02.USD","BK4568","IE00B19Z3B42.SGD","LU0006061336.USD","LU0444971666.USD","BK1584","LU0912757837.SGD","LU1221951129.SGD","LU0882574055.USD","LU2471134952.CNY","LU1043141396.HKD","BK4585","LU0117844026.USD","LU0328353924.USD","LU0737861772.HKD","LU0831103253.SGD","LU1481107354.HKD","LU1282648689.USD","LU1267930813.SGD","LU2347655156.SGD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635840957","title":"BUZZ-Truist raises PT on Madrigal Pharma on liver disease drug opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2635840957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635840957?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:22","pubTimestamp":1778674964,"startTime":"0","endTime":"0","summary":"BUZZ-Truist raises PT on Madrigal Pharma on liver disease drug opportunity** Truist raises PT on Madrigal Pharmaceuticals MDGL.O to $709 from $640, reiterates \"buy\" rating** Brokerage says its physician survey points to a larger opportunity for Rezdiffra, MDGL's drug for metabolic dysfunction-associated steatohepatitis , a fatty liver disease that can cause scarring of the organ ** Says its survey showed physicians prefer Rezdiffra for MASH, citing its safety profile** Adds the survey also showed physician interest in combining Rezdiffra with incretin drugs, a class of metabolic medicines ** Truist raises its U.S. peak estimate for MASH patients on Rezdiffra to 193,000 from 158,000** Truist lifts its worldwide peak adjusted revenue estimate for Rezdiffra to $8.9 billion from $7.7 billion** As of last close, MDGL down 12.4% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL4N41Q13U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDGL","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635784565","title":"Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635784565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635784565?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:52","pubTimestamp":1778673132,"startTime":"0","endTime":"0","summary":"In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-madrigal-pharmaceuticals-mdgl-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-madrigal-pharmaceuticals-mdgl-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634750024","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2634750024","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634750024?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:12","pubTimestamp":1778465576,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634926044","title":"How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634926044","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634926044?lang=en_us&edition=fundamental","pubTime":"2026-05-09 14:42","pubTimestamp":1778308975,"startTime":"0","endTime":"0","summary":"In the first quarter of 2026, Madrigal Pharmaceuticals reported a net loss of US$94.39 million as Rezdiffra generated US$311.3 million in revenue and the company broadened its MASH pipeline, including licensing Arrowhead’s clinical-stage siRNA asset ARO‑PNPLA3.\nBy pairing blockbuster-level Rezdiffra sales with an expanded portfolio of genetic and metabolic MASH candidates, Madrigal is shifting from a single‑drug story toward a broader, combination-focused franchise in liver disease.\nWe’ll...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/how-blockbuster-rezdiffra-sales-and-aropnpla3-licensing-will","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/how-blockbuster-rezdiffra-sales-and-aropnpla3-licensing-will","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434573","title":"Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434573?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:55","pubTimestamp":1778234127,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $964.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-receives-a-buy-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633307174","title":"Madrigal grants inducement equity awards to 47 new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633307174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633307174?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:27","pubTimestamp":1778185675,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted May 1, 2026 equity inducement awards to 47 new non-executive employees under its 2025 Inducement Plan.Awards totaled options for 5,312 shares, 17,589 time-based restricted stock units, and 1,839 performance-based restricted stock units.Options carry an exercise price of USD 513.72; 25% vest on first anniversary of grant date, remaining shares vest 6.25% each quarter.Time-based restricted stock units vest in four equal annual installments; performance-based restricted stock units are tied to relative total shareholder return over three years with potential cliff vesting in Q1 2029.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLcc74NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","SG9999014005.SGD","MDGL","NDAQ","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633262241","title":"Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2633262241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633262241?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:54","pubTimestamp":1778165640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2026 10:54 ET (14:54 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149751","title":"Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149751?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:38","pubTimestamp":1778153885,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $640.00. Devarako...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-madrigal-pharmaceuticals-mdgl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633397143","title":"Madrigal Pharmaceuticals Inc : Clear Street Raises Target Price to $680 From $533","url":"https://stock-news.laohu8.com/highlight/detail?id=2633397143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633397143?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:53","pubTimestamp":1778151231,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.0697},{"period":"1month","weight":-0.0632},{"period":"3month","weight":0.13},{"period":"6month","weight":-0.1701},{"period":"1year","weight":0.7483},{"period":"ytd","weight":-0.1736}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.113604},{"month":6,"riseRate":0.6,"avgChangeRate":0.02606},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}